Evidence map›Paper›PMID 34318891›Full record

ArticleThe Journal of clinical endocrinology and metabolism2021

A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression.

Johannes F Fahrmann, Amanda R Wasylishen, Carolina R C Pieterman, Ehsan Irajizad, Jody Vykoukal, Eunice Murage, Ranran Wu, Jennifer B Dennison, Hansini Krishna, Christine B Peterson and 17 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 3 institutions in 2 countries.

Johannes F FahrmannDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-5088-0198
Amanda R WasylishenDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Carolina R C PietermanDepartment of Surgical Oncology, Section of Surgical Endocrinology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ehsan IrajizadDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jody VykoukalDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Eunice MurageDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ranran WuDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jennifer B DennisonDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0003-3067-0972
Hansini KrishnaDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Christine B PetersonDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Guillermina LozanoDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Hua ZhaoDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Kim-Anh DoDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Daniel M HalperinDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Sunita K AgarwalMetabolic Diseases Branch, the National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Jenny E BlauMetabolic Diseases Branch, the National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-6725-4262
Jaydira Del RiveroDevelopmental Therapeutics Branch, the National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0001-9710-4030
Naris NilubolSurgical Oncology Program, the National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-7348-7804
Mary F WalterCore for Clinical Laboratory Services, the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
James M WelchMetabolic Diseases Branch, the National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Lee S WeinsteinMetabolic Diseases Branch, the National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Menno R VriensDepartment of Surgical Oncology and Endocrine Surgery, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands.
Rachel S van LeeuwaardeCenter for Neuroendocrine Tumors, ENETS Center of Excellence, Netherlands Cancer Institute Amsterdam, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands.
Mark J C van TreijenCenter for Neuroendocrine Tumors, ENETS Center of Excellence, Netherlands Cancer Institute Amsterdam, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands.
Gerlof D ValkCenter for Neuroendocrine Tumors, ENETS Center of Excellence, Netherlands Cancer Institute Amsterdam, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands.
Nancy D PerrierDepartment of Surgical Oncology, Section of Surgical Endocrinology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Samir M HanashDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-4210-1593
The University of Texas MD Anderson Cancer Center · USNational Institutes of Health · USUniversity Medical Center Utrecht · NL

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Convalescent Plasma to Limit Coronavirus Associated ComplicationsUL1TR003167 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KARP, DANIEL D, MCPHERSON, DAVID D · 2019 to 2023
$45.3M
Targeting Tumor Microenvironment-Induced Therapy Resistance in Prostate Cancer Bone MetastasisP50CA140388 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI THOMPSON, TIMOTHY CHARLES · 2009 to 2022
$23.4M
Therapeutic targets and novel anticancer agents for endocrine cancersZIABC011286 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI NILUBOL, NARIS · 2010 to 2025
$16.6M
Role of tissue differentiation factors in endocrine tumorigenesisZIADK075085 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI AGARWAL, SUNITA · 2013 to 2025
$3.2M
Viral miRs and cellular miRs in sepsisR01GM122775 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., LUPU, FLOREA · 2018 to 2020
$1.1M
Identifying Actionable Signatures of Duodenopancreatic Neuroendocrine Tumor Progression in MEN1R21CA252426 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HANASH, SAMIR M · 2020 to 2020
$417k
NCATS NIH HHS UL1 TR003167NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA140388NCI NIH HHS R21 CA252426NIGMS NIH HHS R01 GM122775NIH HHS NIH/NCI R21 CA252426-01NIH HHS R21 CA252426-01
6 · The paper itself

Abstract

contextDuodenopancreatic neuroendocrine tumors (dpNETs) frequently occur in patients with multiple endocrine neoplasia type 1 (MEN1), and metastatic dpNET is the primary cause of disease-related mortality. There is a need for biomarkers that can identify patients with MEN1-related dpNETs that are at high risk of developing distant metastasis. Polyamines have tumor-promoting roles in several cancer types.

objectiveWe hypothesized that MEN1-dpNET-related disease progression is associated with elevated levels of circulating polyamines.

methodsThrough an international collaboration between The University of Texas MD Anderson Cancer Center, the National Institutes of Health, and the University Medical Center Utrecht, plasma polyamine levels were assessed using mass spectrometry in 84 patients with MEN1 (20 with distant metastatic dpNETs [patients] and 64 with either indolent dpNETs or no dpNETs [controls]). A mouse model of MEN1-pNET, Men1fl/flPdx1-CreTg, was used to test time-dependent changes in plasma polyamines associated with disease progression.

resultsA 3-marker plasma polyamine signature (3MP: N-acetylputrescine, acetylspermidine, and diacetylspermidine) distinguished patients with metastatic dpNETs from controls in an initial set of plasmas from the 3 participating centers. The fixed 3MP yielded an area under the curve of 0.84 (95% CI, 0.62-1.00) with 66.7% sensitivity at 95% specificity for distinguishing patients from controls in an independent test set from MDACC. In Men1fl/flPdx1-CreTg mice, the 3MP was elevated early and remained high during disease progression.

conclusionOur findings provide a basis for prospective testing of blood-based polyamines as a potential means for monitoring patients with MEN1 for harboring or developing aggressive disease.

Indexed as

AdultAgedBiomarkers, TumorCase-Control StudiesDisease ProgressionDuodenal NeoplasmsFemaleFollow-Up StudiesHumansMaleMiddle AgedMultiple Endocrine Neoplasia Type 1Neuroendocrine TumorsPancreatic NeoplasmsPolyaminesPrognosisBiomarkers, TumorPolyaminesbiomarkerpancreatic neuroendocrine tumorspolyamines

Identifiers

PMID34318891
PMCPMC8864750
OpenAlexW3184592681

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.